# Two‐Sample Mendelian Randomization Analyses Identified Lipid Species Associated With Intracranial Aneurysm Formation

## TL;DR

This study finds specific lipid types that are linked to the formation of unruptured brain aneurysms, which could help in assessing risk and developing treatments.

## Contribution

The study identifies novel lipid species with causal links to unruptured intracranial aneurysms using Mendelian randomization.

## Key findings

- Seven lipid species were found to be associated with unruptured intracranial aneurysms.
- Some lipids act as risk factors, while others show protective effects against aneurysm formation.
- Reverse MR analysis found no bidirectional causal relationships between lipids and aneurysms.

## Abstract

Intracranial aneurysm (IA) poses a significant health risk, and its formation involves various factors, including lipid metabolism, while former research only focused on the standard lipid. The purpose of this study is to explore 179 lipid variants' impact on unruptured intracranial aneurysms (uIA).

Utilizing GWAS data for lipids and uIAs, MR analyses were employed with pleiotropy, heterogeneity, and sensitivity tests. Reverse MR analyses were then conducted.

MR analyses revealed seven lipids associated with uIAs: TAG (51:3). SE (27:1/16:1), PC (18:2_18:2), TAG (48:1), TAG (48:2), and TAG (51:3) were identified as uIA risk factors, while SE (27:1/18:1) and SM (d34:0) exhibited protective effects. Reverse MR analysis showed no bidirectional causal relationships.

This study identifies specific lipid variants causally linked to uIAs, shedding light on their roles in IA formation. These findings contribute to future research on IA risk assessment and potential therapeutic interventions.

This study investigates the causal relationship between lipid variants and unruptured intracranial aneurysm (uIA) formation using Mendelian randomization. Seven lipid species were identified as risk factors or protective agents for uIAs, offering insights into potential new biomarkers for IA risk assessment and treatment.